Response rate of patients with baseline brain metastases from recently diagnosed non ‐small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status

ConclusionsRT response varies as per tumor molecular status. The presence ofEGFR mutations favors the organ ‐specific response to RT, and is associated with longer OS in patients with NSCLC and BM.Key points This study addressed for the first time the difference in radiotherapy ‐related outcomes in patients with different genotypes of non‐small cell lung cancer (NSCLC) before they received systemic therapy. Results show that response to radiotherapy varies as per tumor molecular status, particularlyEGFR‐mutated tumors, have a favorable response to radiotherapy, contrary toKRAS‐mutated tumors.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research